US FDA found no increased risk of suicidal behaviour or ideation linked to GLP-1s (LLY, NOVOB DC), according to Bloomberg; has asked companies to remove warnings about potential risk from the medicines' labels

US FDA found no increased risk of suicidal behaviour or ideation linked to GLP-1s (LLY, NOVOB DC), according to Bloomberg; has asked companies to remove warnings about potential risk from the medicines' labels.

The FDA's findings regarding GLP-1 medications suggest that concerns about suicidal behavior linked to these drugs are unwarranted, which could lead to a more favorable perception and increased sales for manufacturers like Eli Lilly and Novo Nordisk. Removing the warnings from product labels may enhance market confidence and drive equity prices higher in the pharma sector, particularly for the related stocks.